{"url_path":"/sec/kros/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1664710/0001664710-26-000034-index.html","accession_number":"0001664710-26-000034","cik":"0001664710","ticker":"KROS","issuer_name":"Keros Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1664710/0001664710-26-000034-index.html","primary_entity_key":"0001664710","primary_entity_name":"Keros Therapeutics, Inc."},"word_count":393,"has_tables":true,"body_markdown":"Item 5.07     Submission of Matters to a Vote of Security Holders.\n\nOn June 3, 2026, Keros Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following three proposals: (1) to elect two nominees for director to hold office until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified (“Proposal 1”), (2) to ratify the selection by the Audit Committee of the Board of Directors of the Company (the “Board of Directors”) of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 (“Proposal 2”) and (3) to approve, on an advisory basis, the compensation of the Company’s named executive officers (“Proposal 3”) as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2026 (the “Proxy Statement”). Each of Proposal 1, Proposal 2 and Proposal 3 is described in detail in the Proxy Statement. The final results of the voting on each proposal are set forth below.\n\nProposal 1 – Election of Directors\n\nThe Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows:\n\nNomineeVotes ForVotes WithheldBroker Non-Votes\n\nJean-Jacques Bienaimé10,093,559.275,156,1532,243,514\n\nCharles Newton14,716,598533,1142,243,514\n\nProposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026\n\nThe Company’s stockholders approved Proposal 2. The votes cast were as follows:\n\nVotes ForVotes AgainstVotes Abstain\n\n16,708,279.27783,953994\n\nThere were no broker non-votes with respect to Proposal 2.\n\nProposal 3 – Advisory Vote on Executive Compensation\n\nThe Company’s stockholders approved, on a non-binding advisory basis, Proposal 3. The votes cast were as follows:\n\nVotes ForVotes AgainstVotes AbstainBroker Non-Votes\n\n14,273,625.27974,0492,0382,243,514\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nKEROS THERAPEUTICS, INC.\n\nBy: /s/ Jasbir Seehra\n\n \nJasbir Seehra, Ph.D.\n\nChief Executive Officer\n\nDated: June 3, 2026"}